The companies have teamed to develop an alternative to TAVR that combines the benefits of a less-invasive procedure with the ...

Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...

Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.

Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical ...

The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...

Investing.com -- Edwards Lifesciences (NYSE:EW) stock rose 4.5% following the presentation of new data showing long-term benefits and valve performance of its SAPIEN 3 TAVR.

In July, CMS proposed a significant expansion of the covered procedures list for ASCs, which included many cardiovascular procedures. Here’s what five leaders have said about the expansion of ...

Southcoast Health opens new heart and vascular practice in Taunton, expanding access to advanced cardiology care.

MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart compa ...

Emboline, Inc., a leading innovator in full-body embolic protection devices for transcatheter procedures, today announced completion of patient enrollment in its Protect the Head to Head (ProtectH2H) ...

Edwards Lifesciences Corp. (($EW)) announced an update on their ongoing clinical study. Edwards Lifesciences Corp. is collaborating with World ...

Our initial experience with the DurAVR ® THV System has been very positive, and we look forward to providing definitive comparative evidence which could transform patient care.” “With the first ...